使用连续血糖监测的2型糖尿病患者Dawn现象与甲状腺反馈分位数指数之间的负相关:一项横断面研究

IF 3 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM
Yan Xia, Hong-Jing Chen, Reng-Na Yan, Xiao-Wei Zhu, Han Zhao, Bo Ding, Yun Hu
{"title":"使用连续血糖监测的2型糖尿病患者Dawn现象与甲状腺反馈分位数指数之间的负相关:一项横断面研究","authors":"Yan Xia, Hong-Jing Chen, Reng-Na Yan, Xiao-Wei Zhu, Han Zhao, Bo Ding, Yun Hu","doi":"10.2147/DMSO.S543452","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The mechanism of the dawn phenomenon remains poorly understood, and no targeted therapies are currently available. Emerging evidence suggests thyroid dysfunction may contribute to dawn phenomenon by modulating hepatic glucose output, insulin sensitivity, and β-cell function. This study utilized continuous glucose monitoring (CGM) to identify patients with type 2 diabetes exhibiting dawn phenomenon and to investigate its association with thyroid feedback efficiency.</p><p><strong>Patients and methods: </strong>This study included patients with type 2 diabetes. All patients underwent CGM before any adjustments to their glucose-lowering therapy. The dawn phenomenon was determined if the elevation of blood glucose from 3 AM to 7 AM was more than 1.11 mmol/L. Clinical data, including medications, diabetic complications and comorbidities, biochemical markers, hemoglobin A1c (HbA1c), beta-cell function, and thyroid function, were recorded.</p><p><strong>Results: </strong>A total of 524 patients were included, of whom 265 (50.6%) exhibited the dawn phenomenon. A control group of 216 patients was matched based on HbA1c levels from those without dawn phenomenon using propensity score matching. The standard deviation of blood glucose (SDBG) (2.26 vs 1.78, P=0.001) and coefficient of variation (CV) (22.86 vs 16.97, P<0.001) were significantly higher in the dawn phenomenon group compared to the non-dawn phenomenon group. Thyroid feedback quantile-based index (TFQI) of free thyroxine (FT4) was negatively correlated with the elevation of blood glucose from 3 AM to 7 AM (BG 3-7) (r=-0.211, P=0.002). Low-density lipoprotein (LDL) showed a positive correlation with fasting blood glucose (r=0.242, P=0.001) and BG 3-7 (r=0.123, P=0.083). Regression analysis indicated that TFQI of free triiodothyronine (FT3) (β=-2.399, P<0.001) and LDL (β=0.550, P=0.004) were independent predictors of BG 3-7.</p><p><strong>Conclusion: </strong>The dawn phenomenon significantly correlates with glycemic fluctuation severity and TFQI. These findings indicate the relationship between thyroid hormones and glucose regulation, providing new insights into the mechanism of the dawn phenomenon.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"3465-3475"},"PeriodicalIF":3.0000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439817/pdf/","citationCount":"0","resultStr":"{\"title\":\"Inverse Association Between the Dawn Phenomenon and Thyroid Feedback Quantile-Based Index in Type 2 Diabetes Using Continuous Glucose Monitoring: A Cross-Sectional Study.\",\"authors\":\"Yan Xia, Hong-Jing Chen, Reng-Na Yan, Xiao-Wei Zhu, Han Zhao, Bo Ding, Yun Hu\",\"doi\":\"10.2147/DMSO.S543452\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>The mechanism of the dawn phenomenon remains poorly understood, and no targeted therapies are currently available. Emerging evidence suggests thyroid dysfunction may contribute to dawn phenomenon by modulating hepatic glucose output, insulin sensitivity, and β-cell function. This study utilized continuous glucose monitoring (CGM) to identify patients with type 2 diabetes exhibiting dawn phenomenon and to investigate its association with thyroid feedback efficiency.</p><p><strong>Patients and methods: </strong>This study included patients with type 2 diabetes. All patients underwent CGM before any adjustments to their glucose-lowering therapy. The dawn phenomenon was determined if the elevation of blood glucose from 3 AM to 7 AM was more than 1.11 mmol/L. Clinical data, including medications, diabetic complications and comorbidities, biochemical markers, hemoglobin A1c (HbA1c), beta-cell function, and thyroid function, were recorded.</p><p><strong>Results: </strong>A total of 524 patients were included, of whom 265 (50.6%) exhibited the dawn phenomenon. A control group of 216 patients was matched based on HbA1c levels from those without dawn phenomenon using propensity score matching. The standard deviation of blood glucose (SDBG) (2.26 vs 1.78, P=0.001) and coefficient of variation (CV) (22.86 vs 16.97, P<0.001) were significantly higher in the dawn phenomenon group compared to the non-dawn phenomenon group. Thyroid feedback quantile-based index (TFQI) of free thyroxine (FT4) was negatively correlated with the elevation of blood glucose from 3 AM to 7 AM (BG 3-7) (r=-0.211, P=0.002). Low-density lipoprotein (LDL) showed a positive correlation with fasting blood glucose (r=0.242, P=0.001) and BG 3-7 (r=0.123, P=0.083). Regression analysis indicated that TFQI of free triiodothyronine (FT3) (β=-2.399, P<0.001) and LDL (β=0.550, P=0.004) were independent predictors of BG 3-7.</p><p><strong>Conclusion: </strong>The dawn phenomenon significantly correlates with glycemic fluctuation severity and TFQI. These findings indicate the relationship between thyroid hormones and glucose regulation, providing new insights into the mechanism of the dawn phenomenon.</p>\",\"PeriodicalId\":11116,\"journal\":{\"name\":\"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy\",\"volume\":\"18 \",\"pages\":\"3465-3475\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-09-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439817/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/DMSO.S543452\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DMSO.S543452","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

目的:黎明现象的机制尚不清楚,目前尚无靶向治疗方法。越来越多的证据表明,甲状腺功能障碍可能通过调节肝脏葡萄糖输出、胰岛素敏感性和β细胞功能来促进黎明现象。本研究利用连续血糖监测(CGM)来识别出现黎明现象的2型糖尿病患者,并探讨其与甲状腺反馈效率的关系。患者和方法:本研究纳入2型糖尿病患者。所有患者在调整降糖治疗之前都进行了CGM。如果凌晨3点至7点血糖升高超过1.11 mmol/L,则确定黎明现象。记录临床数据,包括用药、糖尿病并发症和合并症、生化指标、血红蛋白A1c (HbA1c)、β细胞功能和甲状腺功能。结果:共纳入524例患者,其中出现黎明现象265例(50.6%)。对照组216例患者根据无黎明现象患者的HbA1c水平进行倾向评分匹配。血糖标准偏差(SDBG) (2.26 vs 1.78, P=0.001)和变异系数(CV) (22.86 vs 16.97, P)结论:黎明现象与血糖波动严重程度和TFQI显著相关。这些发现表明甲状腺激素和葡萄糖调节之间的关系,为黎明现象的机制提供了新的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Inverse Association Between the Dawn Phenomenon and Thyroid Feedback Quantile-Based Index in Type 2 Diabetes Using Continuous Glucose Monitoring: A Cross-Sectional Study.

Inverse Association Between the Dawn Phenomenon and Thyroid Feedback Quantile-Based Index in Type 2 Diabetes Using Continuous Glucose Monitoring: A Cross-Sectional Study.

Inverse Association Between the Dawn Phenomenon and Thyroid Feedback Quantile-Based Index in Type 2 Diabetes Using Continuous Glucose Monitoring: A Cross-Sectional Study.

Inverse Association Between the Dawn Phenomenon and Thyroid Feedback Quantile-Based Index in Type 2 Diabetes Using Continuous Glucose Monitoring: A Cross-Sectional Study.

Purpose: The mechanism of the dawn phenomenon remains poorly understood, and no targeted therapies are currently available. Emerging evidence suggests thyroid dysfunction may contribute to dawn phenomenon by modulating hepatic glucose output, insulin sensitivity, and β-cell function. This study utilized continuous glucose monitoring (CGM) to identify patients with type 2 diabetes exhibiting dawn phenomenon and to investigate its association with thyroid feedback efficiency.

Patients and methods: This study included patients with type 2 diabetes. All patients underwent CGM before any adjustments to their glucose-lowering therapy. The dawn phenomenon was determined if the elevation of blood glucose from 3 AM to 7 AM was more than 1.11 mmol/L. Clinical data, including medications, diabetic complications and comorbidities, biochemical markers, hemoglobin A1c (HbA1c), beta-cell function, and thyroid function, were recorded.

Results: A total of 524 patients were included, of whom 265 (50.6%) exhibited the dawn phenomenon. A control group of 216 patients was matched based on HbA1c levels from those without dawn phenomenon using propensity score matching. The standard deviation of blood glucose (SDBG) (2.26 vs 1.78, P=0.001) and coefficient of variation (CV) (22.86 vs 16.97, P<0.001) were significantly higher in the dawn phenomenon group compared to the non-dawn phenomenon group. Thyroid feedback quantile-based index (TFQI) of free thyroxine (FT4) was negatively correlated with the elevation of blood glucose from 3 AM to 7 AM (BG 3-7) (r=-0.211, P=0.002). Low-density lipoprotein (LDL) showed a positive correlation with fasting blood glucose (r=0.242, P=0.001) and BG 3-7 (r=0.123, P=0.083). Regression analysis indicated that TFQI of free triiodothyronine (FT3) (β=-2.399, P<0.001) and LDL (β=0.550, P=0.004) were independent predictors of BG 3-7.

Conclusion: The dawn phenomenon significantly correlates with glycemic fluctuation severity and TFQI. These findings indicate the relationship between thyroid hormones and glucose regulation, providing new insights into the mechanism of the dawn phenomenon.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
5.90
自引率
6.10%
发文量
431
审稿时长
16 weeks
期刊介绍: An international, peer-reviewed, open access, online journal. The journal is committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信